Xaliproden (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Xaliproden" in Italian language version.

refsWebsite

Global rank Italian rank

7nih.gov

4^th place

9^th place

6doi.org

2^nd place

7^th place

3archive.org

6^th place

8^th place

3oadoi.org

799^th place

22^nd place

archive.org

C Labie, C Lafon, C Marmouget, P Saubusse, J Fournier, PE Keane, G Le Fur e P Soubrié, Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex, in British Journal of Pharmacology, vol. 127, n. 1, 1999, pp. 139-44, DOI:10.1038/sj.bjp.0702545, PMC 1566010, PMID 10369466.
FH Duong, JM Warter, P Poindron e P Passilly, Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons, in British Journal of Pharmacology, vol. 128, n. 7, 1999, pp. 1385-92, DOI:10.1038/sj.bjp.0702910, PMC 1571767, PMID 10602316.
Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P., Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats, in Invest Radiol, vol. 37, n. 6, 2002, pp. 321-7, DOI:10.1097/00004424-200206000-00003, PMID 12021588.

doi.org

dx.doi.org

C Labie, C Lafon, C Marmouget, P Saubusse, J Fournier, PE Keane, G Le Fur e P Soubrié, Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex, in British Journal of Pharmacology, vol. 127, n. 1, 1999, pp. 139-44, DOI:10.1038/sj.bjp.0702545, PMC 1566010, PMID 10369466.
FH Duong, JM Warter, P Poindron e P Passilly, Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons, in British Journal of Pharmacology, vol. 128, n. 7, 1999, pp. 1385-92, DOI:10.1038/sj.bjp.0702910, PMC 1571767, PMID 10602316.
V Meininger, G Bensimon, WR Bradley, B Brooks, P Douillet, AA Eisen, L Lacomblez, PN Leigh e W Robberecht, Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials, in Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, vol. 5, n. 2, 2004, pp. 107-17, DOI:10.1080/14660820410019602, PMID 15204012.
Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P., Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats, in Invest Radiol, vol. 37, n. 6, 2002, pp. 321-7, DOI:10.1097/00004424-200206000-00003, PMID 12021588.
E Susman, Xaliproden lessens oxaliplatin-mediated neuropathy, in The lancet oncology, vol. 7, n. 4, 2006, p. 288, DOI:10.1016/S1470-2045(06)70639-8, PMID 16598880.
S Wolf, D Barton, L Kottschade, A Grothey e C Loprinzi, Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies, in European journal of cancer (Oxford, England : 1990), vol. 44, n. 11, 2008, pp. 1507-15, DOI:10.1016/j.ejca.2008.04.018, PMID 18571399.

nih.gov

ncbi.nlm.nih.gov

A Appert-Collin, FH Duong, P Passilly Degrace, JM Warter, P Poindron e JP Gies, MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden, in International journal of immunopathology and pharmacology, vol. 18, n. 1, 2005, pp. 21-31, PMID 15698508.
C Labie, C Lafon, C Marmouget, P Saubusse, J Fournier, PE Keane, G Le Fur e P Soubrié, Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex, in British Journal of Pharmacology, vol. 127, n. 1, 1999, pp. 139-44, DOI:10.1038/sj.bjp.0702545, PMC 1566010, PMID 10369466.
FH Duong, JM Warter, P Poindron e P Passilly, Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons, in British Journal of Pharmacology, vol. 128, n. 7, 1999, pp. 1385-92, DOI:10.1038/sj.bjp.0702910, PMC 1571767, PMID 10602316.
V Meininger, G Bensimon, WR Bradley, B Brooks, P Douillet, AA Eisen, L Lacomblez, PN Leigh e W Robberecht, Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials, in Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, vol. 5, n. 2, 2004, pp. 107-17, DOI:10.1080/14660820410019602, PMID 15204012.
Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P., Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats, in Invest Radiol, vol. 37, n. 6, 2002, pp. 321-7, DOI:10.1097/00004424-200206000-00003, PMID 12021588.
E Susman, Xaliproden lessens oxaliplatin-mediated neuropathy, in The lancet oncology, vol. 7, n. 4, 2006, p. 288, DOI:10.1016/S1470-2045(06)70639-8, PMID 16598880.
S Wolf, D Barton, L Kottschade, A Grothey e C Loprinzi, Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies, in European journal of cancer (Oxford, England : 1990), vol. 44, n. 11, 2008, pp. 1507-15, DOI:10.1016/j.ejca.2008.04.018, PMID 18571399.

oadoi.org

V Meininger, G Bensimon, WR Bradley, B Brooks, P Douillet, AA Eisen, L Lacomblez, PN Leigh e W Robberecht, Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials, in Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, vol. 5, n. 2, 2004, pp. 107-17, DOI:10.1080/14660820410019602, PMID 15204012.
E Susman, Xaliproden lessens oxaliplatin-mediated neuropathy, in The lancet oncology, vol. 7, n. 4, 2006, p. 288, DOI:10.1016/S1470-2045(06)70639-8, PMID 16598880.
S Wolf, D Barton, L Kottschade, A Grothey e C Loprinzi, Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies, in European journal of cancer (Oxford, England : 1990), vol. 44, n. 11, 2008, pp. 1507-15, DOI:10.1016/j.ejca.2008.04.018, PMID 18571399.